ArticleLa Radiologia medica2021
Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features.
Article in La Radiologia medica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.Abdominal radiology (New York) · 2024Pooled it
- Imaging in localized intrahepatic bile duct dilatation: a pictorial review of diagnostic and differential approaches.Insights into imaging · 2026Article
- Differentiating scirrhous hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma based on Gd-EOB-DTPA-enhanced MRI and serum biomarkers in an HBV-positive high-risk cohort: a multi-center study.European radiology · 2026Article
- MRI findings of intrahepatic cholangiocarcinoma with sarcomatoid differentiation: a retrospective case series.BMC medical imaging · 2026Article
- Differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma with MRI and tumor markers: a multi-center study.European radiology · 2026Article
- Multi-algorithm radiomics machine learning models integrating ultrasound imaging and inflammation-immune features for hepatic metastases identification.BMC medical imaging · 2025Article
- Recent Advances in Magnetic Resonance Imaging for the Diagnosis of Liver Cancer: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2025Review
- Multiparametric MRI-Based Intratumoral and Peritumoral Radiomics for Distinguishing Solitary Intrahepatic Mass-Forming Cholangiocarcinoma From Colorectal Liver Metastases.Cancer medicine · 2025Article
- An MRI-based fusion model for preoperative prediction of perineural invasion status in patients with intrahepatic cholangiocarcinoma.World journal of surgical oncology · 2025Article
- MRI management of focal liver lesions: what a beginner cannot fail to know.Frontiers in oncology · 2025Review
- Scientific Status Quo of Small Renal Lesions: Diagnostic Assessment and Radiomics.Journal of clinical medicine · 2024Review
- An Informative Review of Radiomics Studies on Cancer Imaging: The Main Findings, Challenges and Limitations of the Methodologies.Current oncology (Toronto, Ont.) · 2024Review
- Preoperative MRI features predicting very early recurrence of intrahepatic mass-forming cholangiocarcinoma after R0 resection: a comparison with the AJCC 8th edition staging system.Abdominal radiology (New York) · 2024Article
- Establishment and validation of a nomogram containing cytokeratin fragment antigen 21-1 for the differential diagnosis of intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Frontiers in oncology · 2024Article
- Radiomics and machine learning analysis by computed tomography and magnetic resonance imaging in colorectal liver metastases prognostic assessment.La Radiologia medica · 2023Article
- Radiomics and artificial intelligence analysis by T2-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging to predict Breast Cancer Histological Outcome.La Radiologia medica · 2023Article
- Artificial Intelligence to Early Predict Liver Metastases in Patients with Colorectal Cancer: Current Status and Future Prospectives.Life (Basel, Switzerland) · 2023Review
- Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.Quantitative imaging in medicine and surgery · 2023Article
- Prognostic Assessment of Gastropancreatic Neuroendocrine Neoplasm: Prospects and Limits of Radiomics.Diagnostics (Basel, Switzerland) · 2023Review
- Artificial intelligence and radiation effects on brain tissue in glioblastoma patient: preliminary data using a quantitative tool.La Radiologia medica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrahepatic cholangiocarcinoma (ICC) is the second most common type of primary hepatic malignancy. Aim of this work is to analyse the features of ICC and its differential diagnosis at MRI, assessing two categories intraparenchymal and peribiliary lesions.
methodsThe study population included 88 patients with histological diagnosis of ICCs: 61 with mass-forming type, 23 with periductal-infiltrating tumours and 4 with intraductal-growing type. As a control study groups, we identified: 86 consecutive patients with liver colorectal intrahepatic metastases (mCRC) (groups A); 35 consecutive patients with peribiliary metastases (groups B); 62 consecutive patients (groups C) with hepatocellular carcinoma (HCC); 18 consecutive patients (groups D) with combined hepatocellular cholangiocarcinoma (cHCC-CCA); and 26 consecutive patients (groups E) with hepatic hemangioma. For all lesions, magnetic resonance (MR) features were assessed according to Liver Imaging Reporting and Data System (LI-RADS) version 2018. The liver-specific gadolinium ethoxybenzyl dimeglumine-EOB (Primovist, Bayer Schering Pharma, Germany), was employed. Chi-square test was employed to analyse differences in percentage values of categorical variable, while the nonparametric Kruskal-Wallis test was used to test for statistically significant differences between the median values of the continuous variables. However, false discovery rate adjustment according to Benjamin and Hochberg for multiple testing was considered.
resultsT1- and T2-weighted signal intensity (SI), restricted diffusion, transitional phase (TP) and hepatobiliary phase (HP) aspects allowed the differentiation between study group (mass-forming ICCs) and each other control group (A, C, D, E) with statistical significance, while arterial phase (AP) appearance allowed the differentiation between study group and the control groups C and D with statistical significance and PP appearance allowed the differentiation between study group and the control groups A, C and D with statistical significance. Instead, no MR feature allowed the differentiation between study group (periductal-infiltrating type) and control group B.
conclusionT1 and T2 W SI, restricted diffusion, TP and HP appearance allowed the differentiation between mass-forming ICCs and mimickers with statistical significance, while AP appearance allowed the differentiation between study group and the control groups C and D with statistical significance and PP appearance allowed the differentiation between study group and the control groups A, C and D.
Indexed as
Identifiers
34843029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.